Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate

Arrowhead Pharmaceuticals Inc ARWR and Horizon Therapeutics plc HZNP have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout.
Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals’ ARO-XDH, an investigational RNAi therapy.
The deal includes $660 million in downstream milestones and potential royalties in the low- to mid-teens.
Horizon will handle clinical development and worldwide commercialization, with Arrowhead responsible for preclinical development.
Price Action: ARWR shares are up 4.13% at $89.18, and HZNP stock is up 0.17% at $94.77 during the market trading session on the last check Monday.

Momentum18.16

GrowthNot Available

QualityNot Available

Value61.10

Short

Medium

Long